RxDoctor Payments Data

Sharon Miller, DO

Gastroenterology · Hermitage, PANPI 1982647483

Payments from drug & device makers

$21,827in general payments, 2019–2025

Across 97 payments — averaging $225.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$18K
  • UCB Biosciences Inc.$2K
  • Johnson & Johnson$979
  • Takeda Pharmaceuticals U.S.A., Inc.$122
  • Pfizer$58
  • Medline Industries LP$47
  • plus $56 from 4 others

What the payments were for

  • Speaking & faculty fees$14,85076%
  • Travel & lodging$2,83614%
  • Food & beverage$1,6508%
  • Education$2411%

General payments by program year

19
20
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,827 in reported general payments places this provider in the 80th percentile of 935 gastroenterology providers in Pennsylvania.

See all gastroenterology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$52,463
Medicare patients
302
Services billed
463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira PenAdalimumab13$177,104
XeljanzTofacitinib Citrate23$130,156
LinzessLinaclotide99$70,222
XifaxanRifaximin17$54,488
Mesalamine41$24,333
Alosetron Hcl11$21,810
Dexlansoprazole DrDexlansoprazole27$12,377
Ursodiol30$7,550
RasuvoMethotrexate/Pf12$6,617
Mesalamine DrMesalamine15$6,068
Sucralfate112$5,393
MovantikNaloxegol Oxalate11$4,561
Esomeprazole Magnesium72$4,207
Lubiprostone21$3,854
Omeprazole368$3,742

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerXeljanz$58$130,15623 claims
AbbVieLinzess$18,315$70,22299 claims
Redhill Biopharma Inc.Movantik$13$4,56111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 gastroenterology providers in Pennsylvania.

Other gastroenterology in Hermitage

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →